Advancing Neurological Health Through Innovative Vaccine Development
At Nuravax, our research pipeline is robust and forward-thinking, dedicated to developing vaccines for individuals at risk of Alzheimer’s disease, tauopathies, Parkinson’s disease, and other α-synucleopathies. Our projects are fueled by prestigious grants, including NIA and NINDS R21s, R01s, and U01 awards, reflecting the trust and recognition in our scientific community.